Hudelist, G., Fritzer, N., Thomas, A., Niehues, C., Oppelt, P., Haas, D., & Salzer, H
CagriSema produces higher rates of nausea (55% versus 31%) and vomiting (26% versus 12%) compared to tirzepatide in their respective clinical trials
We believe that it is reasonable to require an enhanced disclosure to the patient who may be prescribed one of these drugs that this molecule is not as well-characterized as drugs that would normally be dispensed to patients, and the patient needs to understand that there may be a higher risk profile, and they should only be taken under the care of a physician, he said
I had the privilege of making medications and design treatment plans and drug plans for so many individuals helping them in their health and wellness journey